Repository logo
 

Ionic immune suppression within the tumour microenvironment limits T cell effector function.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Eil, Robert 
Vodnala, Suman K 
Clever, David 
Klebanoff, Christopher A 
Sukumar, Madhusudhanan 

Abstract

Tumours progress despite being infiltrated by tumour-specific effector T cells. Tumours contain areas of cellular necrosis, which are associated with poor survival in a variety of cancers. Here, we show that necrosis releases intracellular potassium ions into the extracellular fluid of mouse and human tumours, causing profound suppression of T cell effector function. Elevation of the extracellular potassium concentration ([K+]e) impairs T cell receptor (TCR)-driven Akt-mTOR phosphorylation and effector programmes. Potassium-mediated suppression of Akt-mTOR signalling and T cell function is dependent upon the activity of the serine/threonine phosphatase PP2A. Although the suppressive effect mediated by elevated [K+]e is independent of changes in plasma membrane potential (Vm), it requires an increase in intracellular potassium ([K+]i). Accordingly, augmenting potassium efflux in tumour-specific T cells by overexpressing the potassium channel Kv1.3 lowers [K+]i and improves effector functions in vitro and in vivo and enhances tumour clearance and survival in melanoma-bearing mice. These results uncover an ionic checkpoint that blocks T cell function in tumours and identify potential new strategies for cancer immunotherapy.

Description

Keywords

Animals, Cations, Monovalent, Humans, Immune Tolerance, Immunotherapy, Kv1.3 Potassium Channel, Male, Melanoma, Membrane Potentials, Mice, Necrosis, Potassium, Proto-Oncogene Proteins c-akt, Receptors, Antigen, T-Cell, Signal Transduction, Survival Analysis, T-Lymphocytes, TOR Serine-Threonine Kinases, Tumor Escape, Tumor Microenvironment

Journal Title

Nature

Conference Name

Journal ISSN

0028-0836
1476-4687

Volume Title

537

Publisher

Springer Science and Business Media LLC
Sponsorship
Wellcome Trust (105663/Z/14/Z)